Skip to main content
Erschienen in: Supportive Care in Cancer 11/2013

01.11.2013 | Original Article

Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation

verfasst von: Tove Godskesen, Peter Nygren, Karin Nordin, Mats Hansson, Ulrik Kihlbom

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

In cancer, phase 1 clinical trials on new drugs mostly involve patients with advanced disease that is unresponsive to standard therapy. The purpose of this study was to explore the difficult ethical problems related to patient information and motives for participation in such trials.

Method

A descriptive and explorative qualitative design was used. Fourteen cancer patients from three different phase 1 trials in end-stage cancer were interviewed. The interviews were analysed using qualitative content analysis.

Results

The patients expressed unrealistic expectations of therapeutic benefit and inadequate understanding of the trials’ purpose, so-called therapeutic misconception. However, they reported a positive attitude towards participation. Thus, the patients valued the close and unique medical and psychological attention they received by participating. Participation also made them feel unique and notable.

Conclusions

Patients with end-stage cancer participating in phase 1 clinical trials are unaware of the very small potential for treatment benefit and the risk of harm. Trial participation may offer hope and social–emotional support and a strategy for coping with the emotional stress associated with advanced cancer and may, consequently, improve emotional well-being.
Literatur
1.
Zurück zum Zitat Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5:319–329PubMedCrossRef Appelbaum PS, Roth LH, Lidz C (1982) The therapeutic misconception: informed consent in psychiatric research. Int J Law Psychiatry 5:319–329PubMedCrossRef
2.
Zurück zum Zitat Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, New York Beauchamp TL, Childress JF (2009) Principles of biomedical ethics. Oxford University Press, New York
3.
Zurück zum Zitat Cohen L, de Moor C, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91:1949–1955PubMedCrossRef Cohen L, de Moor C, Amato RJ (2001) The association between treatment-specific optimism and depressive symptomatology in patients enrolled in a phase I cancer clinical trial. Cancer 91:1949–1955PubMedCrossRef
4.
Zurück zum Zitat Cox K (2000) Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. Psychooncol 9:314–322CrossRef Cox K (2000) Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants’ experiences. Psychooncol 9:314–322CrossRef
5.
Zurück zum Zitat Cox K (2002) Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46:31–38PubMedCrossRef Cox K (2002) Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trials. Patient Educ Couns 46:31–38PubMedCrossRef
6.
Zurück zum Zitat Daugherty CK (1999) Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 17:1601–1617PubMed Daugherty CK (1999) Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol 17:1601–1617PubMed
7.
Zurück zum Zitat Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef Daugherty CK, Banik DM, Janish L, Ratain MJ (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef
8.
Zurück zum Zitat Eriksson K (2001) Vårdvetenskap som akademisk disciplin. (Health care science as an academic discipline). Åbo Akademi University, Turku Eriksson K (2001) Vårdvetenskap som akademisk disciplin. (Health care science as an academic discipline). Åbo Akademi University, Turku
9.
Zurück zum Zitat Fussenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152–1160PubMedCrossRef Fussenich LM, Desar IM, Peters ME, Teerenstra S, van der Graaf WT, Timmer-Bonte JN, van Herpen CM (2011) A new, simple and objective prognostic score for phase I cancer patients. Eur J Cancer 47:1152–1160PubMedCrossRef
10.
11.
Zurück zum Zitat Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105–112PubMedCrossRef Graneheim UH, Lundman B (2004) Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 24:105–112PubMedCrossRef
12.
Zurück zum Zitat Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Brit J Cancer 89:1166–1171PubMedCrossRef Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC (2003) Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Brit J Cancer 89:1166–1171PubMedCrossRef
13.
Zurück zum Zitat Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134–2140PubMedCrossRef Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C (2002) Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med 347:2134–2140PubMedCrossRef
14.
Zurück zum Zitat Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787–792PubMedCrossRef Italiano A, Massard C, Bahleda R, Vataire AL, Deutsch E, Magne N, Pignon JP, Vassal G, Armand JP, Soria JC (2008) Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787–792PubMedCrossRef
15.
Zurück zum Zitat Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29:61–68PubMedCrossRef Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ (2011) What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J Clin Oncol 29:61–68PubMedCrossRef
16.
Zurück zum Zitat Kahneman D, Tversky A (1979) Prospect theory—analysis of decision under risk. Econometrica 47:263–291CrossRef Kahneman D, Tversky A (1979) Prospect theory—analysis of decision under risk. Econometrica 47:263–291CrossRef
17.
Zurück zum Zitat Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3:57–68PubMedCrossRef Kass N, Taylor H, Fogarty L, Sugarman J, Goodman SN, Goodwin-Landher A, Carducci M, Hurwitz H (2008) Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics 3:57–68PubMedCrossRef
18.
Zurück zum Zitat Kvale S (1997) Den kvalitativa forskningsintervjun. Studentlitteratur, Lund Kvale S (1997) Den kvalitativa forskningsintervjun. Studentlitteratur, Lund
19.
Zurück zum Zitat Kvale S (2007) Doing interviews. Sage, Thousand Oaks Kvale S (2007) Doing interviews. Sage, Thousand Oaks
20.
Zurück zum Zitat Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5:65–72PubMedCrossRef Le Tourneau C, Dieras V, Tresca P, Cacheux W, Paoletti X (2010) Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol 5:65–72PubMedCrossRef
21.
Zurück zum Zitat Mcgraw JG (1995) Loneliness, its nature and forms—an existential perspective. Man World 28:43–64CrossRef Mcgraw JG (1995) Loneliness, its nature and forms—an existential perspective. Man World 28:43–64CrossRef
22.
Zurück zum Zitat Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef Meropol NJ, Weinfurt KP, Burnett CB, Balshem A, Benson AB, Castel L, Corbett S, Diefenbach M, Gaskin D, Li Y, Manne S, Marshall J, Rowland JH, Slater E, Sulmasy DP, Van Echo D, Washington S, Schulman KA (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef
23.
Zurück zum Zitat Moore S (2001) A need to try everything: patient participation in phase I trials. J Adv Nurs 33:738–747PubMedCrossRef Moore S (2001) A need to try everything: patient participation in phase I trials. J Adv Nurs 33:738–747PubMedCrossRef
24.
Zurück zum Zitat Ohlen J (2002) Practical wisdom: competencies required in alleviating suffering in palliative care. J Palliat Care 18:293–299PubMed Ohlen J (2002) Practical wisdom: competencies required in alleviating suffering in palliative care. J Palliat Care 18:293–299PubMed
25.
Zurück zum Zitat Patton MQ (2002) Qualitative research and evaluation methods. Sage, London Patton MQ (2002) Qualitative research and evaluation methods. Sage, London
26.
Zurück zum Zitat Saeteren B, Lindstrom UA, Naden D (2011) Latching onto life: living in the area of tension between the possibility of life and the necessity of death. J Clin Nurs 20:811–818PubMedCrossRef Saeteren B, Lindstrom UA, Naden D (2011) Latching onto life: living in the area of tension between the possibility of life and the necessity of death. J Clin Nurs 20:811–818PubMedCrossRef
27.
Zurück zum Zitat Stolberg SG (2000) Teenager’s death is shaking up field of human gene-therapy experiments. New York Times, New York Stolberg SG (2000) Teenager’s death is shaking up field of human gene-therapy experiments. New York Times, New York
28.
Zurück zum Zitat Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP (2010) The culture of faith and hope patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116:3702–3711PubMedCrossRef Sulmasy DP, Astrow AB, He MK, Seils DM, Meropol NJ, Micco E, Weinfurt KP (2010) The culture of faith and hope patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 116:3702–3711PubMedCrossRef
Metadaten
Titel
Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation
verfasst von
Tove Godskesen
Peter Nygren
Karin Nordin
Mats Hansson
Ulrik Kihlbom
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1891-7

Weitere Artikel der Ausgabe 11/2013

Supportive Care in Cancer 11/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.